MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Property, Plant & Equipment (Net) · Q3 FY2026 · quarter ended Sep 2026
Property, plant & equipment (net) rises 201.5% from a year ago
Property, plant & equipment (net) stood at $7.61M at the end of Q3 FY2026, up 201.5% from a year earlier and up 2.5% from the prior quarter. Over 3 fiscal years it compounded at +56.4% a year.
Context
- Property, plant & equipment (net) amounted to 1.5% of total assets at the end of Q3 FY2026, up 0.9 pp from a year earlier.
- Property, plant & equipment (net) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +201.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 3.22M USD
- Year-over-year change
- +168.7%
- 3-year CAGR
- +56.4%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.22M | +168.7% |
| FY2024 | 2024-12-31 | 1.2M | +80.3% |
| FY2023 | 2023-12-31 | 665K | -21.0% |
| FY2022 | 2022-12-31 | 842K | — |
Property, Plant & Equipment (Net) vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +201.5% is the 2nd highest of 8, against a peer median of -3.9%.
- Property, plant & equipment (net) amounts to 1.5% of total assets for MBX, versus a peer median of 0.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €134.94M EUR | +32.6% | +4.3% | 5.6% | |
| Mar 2026 | $26.98M USD | -2.9% | +41.7% | 6.9% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $11.65M USD | — | — | 1.0% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $7.61M USD | +201.5% | +56.4% | 1.5% |
| Jun 2026 | $4.01M USD | +414.1% | -60.9% | 0.8% | |
| Sep 2026 | $3.26M USD | -3.9% | +7.1% | 0.7% | |
| Mar 2026 | $1.25M USD | -44.3% | -9.6% | 0.5% | |
| Mar 2026 | $208K USD | -45.8% | -33.9% | 0.1% | |
| Mar 2026 | $67K USD | -99.3% | -73.2% | 0.1% | |
| Peer median (excluding MBX) | — | -3.9% | -9.6% | 0.8% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.